Pharmacokinetics of Medication for Severe Ulcerative Colitis
common.study.values.description
“Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis”
This is an open-label, prospective, observational study with the primary objective to characterize the pharmacokinetics of infliximab in patients with Acute Severe Ulcerative Colitis.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Infliximab
Patients will receive infliximab at the discretion of their physician as part of standard of care.
participant.views.study.view.additional
participant.views.study.view.scientific-title
Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
common.study.values.clinical-trial-id
NCT03765450
participant.views.study.view.id
dNk5Le
